PMID: 9557809Apr 29, 1998Paper

Plasma pharmacokinetics of intravenous and intramuscular furosemide in the camel (Camelus dromedarius)

Research in Veterinary Science
B H AliA K Bashir

Abstract

Single bolus intravenous (i.v.) and intramuscular (i.m.) doses of furosemide (1.5 mg kg(-1)) were administered in a crossover design to three female and three male adult, dromedary camels. Plasma furosemide concentrations were assayed by HPLC and sodium, potassium and chloride concentrations were measured using ion-selective electrodes. Plasma furosemide concentration-time plots indicated multi-compartment disposition, and there was considerable intersubject variability in the pharmacokinetic parameters. The mean (SD) i.v. terminal elimination half-life was 118 (67) minutes. The systemic clearance was 5.4 (1.2) ml min(-1) kg(-1). and the steady-state volume of distribution was 0.43 (0.14) litre kg(-1). The mean absorption time after i.m. dosing was 33 (62) minutes, while the absolute bioavailability was 71 (20) per cent. The glucuronide metabolite of furosemide was not detected in plasma. Clearance was lower, volume of distribution was larger, and half-life was longer compared with published data for dogs, horses, rats and humans. Plasma potassium and sodium concentrations were significantly diminished (P<0.05) by an average of 35.6 per cent (two to six hours post-dose) and 11.3 per cent (eight hours post-dose), respectively. P...Continue Reading

References

Jul 1, 1979·Clinical Pharmacokinetics·R E Cutler, A D Blair
Sep 1, 1992·Journal of Veterinary Pharmacology and Therapeutics·J HiraiT Taneike
May 1, 1990·Clinical Pharmacokinetics·L L Ponto, R D Schoenwald
Mar 1, 1990·Journal of Veterinary Pharmacology and Therapeutics·A J StevensonP Beaumier
Jan 1, 1989·Comparative Biochemistry and Physiology. A, Comparative Physiology·Z Ben-ZviR Yagil
Jan 1, 1988·Veterinary Research Communications·B H Ali
Jan 1, 1985·Archives of Internal Medicine·Y YagilP Mogle
Oct 1, 1982·Biopharmaceutics & Drug Disposition·M M Hammarlund, L K Paalzow
Apr 1, 1995·Journal of Veterinary Pharmacology and Therapeutics·Z Ben-ZviR Yagil
Jun 1, 1994·Journal of Veterinary Pharmacology and Therapeutics·A J StevensonS Kacew
Apr 1, 1996·Journal of Veterinary Pharmacology and Therapeutics·T M DykeW W Muir
Sep 1, 1996·Comparative Biochemistry and Physiology. Part C, Pharmacology, Toxicology & Endocrinology·B H AliA K Bashir

❮ Previous
Next ❯

Citations

Jul 25, 2003·European Journal of Drug Metabolism and Pharmacokinetics·B H Ali
Sep 9, 2006·Journal of Veterinary Pharmacology and Therapeutics·I MahmoodR P Hunter
May 7, 2010·Journal of Veterinary Pharmacology and Therapeutics·Z ZhaoX Meng
Nov 20, 2016·Biomedical Chromatography : BMC·Ibrahim A WasfiWaleed A Al Ali
Feb 19, 2002·Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine·H A ElsheikhA K Bashir
Dec 15, 2020·Journal of Veterinary Pharmacology and Therapeutics·Duygu Durna CorumKamil Uney
Aug 25, 2021·Journal of Veterinary Pharmacology and Therapeutics·Gul CetinKamil Uney

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.